>  2020 APBG Webinar Series:Bias Control in Observational Studies

15 July 2020 10am-11am  Eastern Australia Time - Sydney

Bias Control in Observational Studies

Observational studies are often thought of as simple studies to design, analyse and report. This myth is busted when I talk about the approaches to comparing treatment outcomes for patients from non-randomised designs. The talk will introduce basic concepts of bias and methods to control for this in observational studies. 

Speaker Bio

Alan is currently Principal Research Scientist at Eli Lilly working in Real World Analytics (RWA) with a focus on specialized analysis that supports this RWE. Prior to this he was the Asia Pacific Director of the Health Outcomes and Health Economics, Life Sciences for OPTUM. Whilst at Eli Lilly he has been the Health Outcomes and Statistics Asia Pacific statistical sciences group leader and manager. He has worked for SPSS Australasia as a Technical Support and Training Consultant; at Macquarie University Practical Demonstrator/Tutor in statistics. He also worked as a Consultant Biostatistician for 5 years in Public Health NSW Health Department. Following that he was a Senior Biostatistician at the George Institute which is affiliated with UNSW where he worked on epidemiological studies and RCTs. Before joining Eli Lilly in 2002 he also took a position at the NSW Department of Corrective Services as Deputy Director of the Research & Statistics, Sydney.

Alan has worked in observational research for 25 years and his interests include the design and analysis of observational studies with a focus on methodologies related to subgroup identification as well as selection bias adjustment tools including matching, propensity score analysis and model averaging. He is also interested in Health Outcomes and statistical approaches used to help support the reimbursement of medicines including NMA.

He has A-STAT Professional Accreditation with the Statistical Society of Australia (SSA). He is an active member and Chair of the Australian Pharmaceutical Biostatistics Group (APBG)

>  2020 APBG Webinar Series:Cluster Randomised Trials

Tue 4 Feb 2020 9am – 10am Eastern Australia Time - Sydney

Speaker Bio

Jessica Kasza is a senior lecturer in the Biostatistics Unit located in the School of Public Health and Preventive Medicine at Monash University. After completing a PhD in 2010 at the University of Adelaide, she spent time at the University of Copenhagen, before returning to the University of Adelaide. She has been at Monash University since 2013. She leads the development of statistical methodology for longitudinal cluster randomised trials, including the stepped wedge and cluster cross over designs, and has interests in the comparison of healthcare providers and causal inference. Jessica is the Vice President of the Statistical Society of Australia. You can find out more about her research at jkasza.netlify.com

>  2019 APBG Annual General Meeting

Mon 9 Dec 2019 2:30pm – 5pm :George Institute, Level 5, 1 King St, Newtown

Talk: Early stopping of clinical trials: impacts on treatment effects, meta-analyses and cost-effectiveness

Ian Marschner is Professor of Biostatistics at The University of Sydney, in the NHMRC Clinical Trials Centre

>  2019 APBG Webinar Series

14 May 2019: Practical applications and lessons learnt from case studies of biomarker analysis in drug development

William Reece, Statistical Fellow & Director, Commercial Support Services, Covance

25 July 2019: Generalizing from RCTs to real world populations

Mark Belger , Principal Research Scientist, Eli Lilly

September 2019: Upcoming: Joint Webinar with PSI

>  2016 Mid Year Seminar - Quasi-Experimental designs

Stepped-Wedge Trials - Serigne Lo 2016

Interrupted Time Series - Timothy Dobbins 2016

Quasi Experimental Designs - Ines Krass 2016

>  APBG Constitution.doc (34K)


>  2015. Casual Inference in Randomised Trails
Dr. Richard Emsley - Monday 7 Dec 2015


>  2015. RWE Workshop

APBG RWE Workshop Talk 1 - Alan Brnabic


APBG RWE Workshop Talk 2 - David Grainger


APBG RWE Workshop Talk 3 - Laurent Billot


APBG RWE Workshop Talk 4 - John McNeil


>  2014. APBG Mid Year Meeting 2014 Shelia Bird talk


>  2013. APBG 2013_AGM _IanM_talk.pdf


>  2013. APBG Constitution 25 Feb 2013.pdf


>  2012.  MID Year Meeting


Log-binomial regression - Sydney APBG 2012 (Laurent Billot) v4.pdf (737K)


Missing Data in Clinical Trials Trial APBG 22 Aug 2012.pdf (296K)


Hot topics in stats 22AUG2012v2.pdf

>  2013. Mid Year Meeting 2013.pdf


Biomarker choice.pdf


FDA Missing Data2.pdf


Heritier_JM_SAFE_TBI_v03_July_2013.pdf (1.1M)



>  2011. MartinBlandReportingclinicaltrialswithconfidence.pdf (53K)
>  2010.  APBG AGM


APBG_AGM_Dec2010_final.pdf (1.1M)


>  2008.  Monthly Notice - ST_July08.pdf
>  2008.  Integrating Statistical Ideas into mathematics 2 Workshop 6 Aug 08.pdf (40K)
>  2008.  Monthly Notice - 2008 Oct.pdf)


>  2007.  Indirect Comparison


ICHAWorkshopMar2007.pdf (54K)


Stats Indirect Workshop (b) Kris and Bill.pdf








Annie Solterbeck v2.pdf


APBG Session 4.pdf

  • LinkedIn Social Icon
  • w-facebook
  • Twitter Clean
  • Google+ Clean

© 2015 APBG Australian Pharmaceutical Biostatistic Group.  Proudly created with Wix.com


Copyright Notice

Copyright on all material on this website is owned by APBG unless otherwise indicated. APBG authorises you to copy any material published by APBG placed on this Website for non-commercial use only, provided that any copied material from the Website retains all copyright or other proprietary notices and any disclaimer contained thereon.

APBG makes no representation as to the accuracy or any other aspect of the information contained on servers linked to the Website via hyperlinks from APBG Website.


Disclaimer Notice

The content of APBG's Website is provided for information purposes only. APBG makes no claim as to the accuracy of the content contained in the Website. APBG does not accept liability to any person for the information or advice provided on this Website or incorporated into it by reference. APBG does not accept liability for loss or damages incurred by any person as a result of reliance upon the content of this Website or any other information incorporated by reference.

This information is provided on the basis that all persons accessing the Website undertake the responsibility for assessing the accuracy of its content and that they rely on it entirely at their own risk.